Dr. Jesse Raia Qualliotine, MD

Dr. Qualliotine practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Qualliotine's NPI, 1003239948, was assigned on January 29, 2014. Dr. Qualliotine graduated from The Johns Hopkins University School of Medicine in 2016. Dr. Qualliotine's California license number on file is A151988.

Dr. Qualliotine's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Qualliotine's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Qualliotine is also affiliated with Hillcrest Medical Center. The medical group on file is UCSF Medical Group. Dmand AI also links Dr. Qualliotine to 4 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Qualliotine practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Qualliotine's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Qualliotine is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. Qualliotine has a license on file in California.

CMS data shows 118 Medicare services from Dr. Qualliotine across 4 procedure codes in 2024, for 74 Medicare patients. Medicare paid $11,296 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 74 Medicare patients who saw Dr. Qualliotine in 2024. The largest group is 65 to 74, with 33 patients. 70% of them have high blood pressure, and 68% have high cholesterol. 46% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Qualliotine's median patient age at 63, with 38% women.

In 2024, Dr. Qualliotine wrote 36 Medicare Part D claims for 16 patients. 94% of them were for generic drugs. CMS names the drug for 29 of them, across 1 drug with 11 or more claims each, at $118 in total drug cost. In 2021, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Qualliotine for performance year 2024, reported as part of a group. Dr. Qualliotine accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 32 papers to Dr. Qualliotine, published from 2015 to 2023. 2019 was the busiest year, with 8. The most frequent topics are Carcinoma, Squamous Cell, Oropharyngeal Neoplasms and Papillomavirus Infections. Dr. Qualliotine has published most often in Ann Otol Rhinol Laryngol. Dr. Qualliotine's most frequent co-authors are Joseph A. Califano, MD, Adam S. Deconde, MD and Carole Fakhry, MD.

Dmand AI links Dr. Qualliotine to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 27 general payments to Dr. Qualliotine from 6 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 51% of the total. Intuitive Surgical, Inc. paid the most, $1,029.

Dr. Qualliotine graduated from The Johns Hopkins University School of Medicine in 2016.

Dr. Qualliotine is in network with 10 carriers, including Elevance, United Healthcare and Aetna. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.